Healthcare
Live Price
Offline$8.60
+5.33% today
1Y Change
+58.45%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Candel Therapeutics, Inc. (CADL) is a Healthcare stock with a market cap of $420.00M. The stock last traded around $8.60 and up 58.4% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +58.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +58.6%, free cash flow -43.9% with operating margin 0.0% and ROIC -41.4%. Stock Foundry combines CADL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CADL
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CADL Max Drawdown
-37.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CADL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$125.0K
+0.0% YoY
FY Net Income
-$36.1M
-92.2% YoY
Free Cash Flow
-$24.1M
+26.5% YoY
Revenue Growth
+0.0%
EPS Growth
+58.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 125K | 125K |
| Gross Profit | -845K | -990K | -24M | 125K | -14M |
| Operating Income | -48M | -33M | -38M | -35M | -26M |
| EBITDA | -47M | -52M | -37M | -16M | -25M |
| Net Income | -38M | -55M | -38M | -19M | -36M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 120M | 103M | 35M | 70M | 83M |
| Total Assets | 125M | 107M | 41M | 79M | 89M |
| Total Liabilities | 73M | 41M | 28M | 31M | 25M |
| Shareholder Equity | 52M | 66M | 13M | 48M | 64M |
| Total Debt | 2M | 13M | 23M | 23M | 560K |
| Net Debt | -118M | -89M | -13M | -47M | -82M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+29.3% YoY
Capital Expenditures
2M
-41.5% YoY
Free Cash Flow
24M
+26.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.4%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.